T1	Treatment 147 149	GH
T2	Treatment 306 318	GH treatment
T3	Treatment 491 509	placebo-controlled
T4	Treatment 525 632	Urinary steroid profile was used to estimate 11betaHSD type 1 and 2 (11betaHSD1 and 11betaHSD2) activities.
T5	Treatment 633 647	Abdominal s.c.
T6	Treatment 648 717	and visceral adipose tissues were measured using computed tomography.
T7	Treatment 718 847	Glucose disposal rate (GDR) obtained during a euglycaemic-hyperinsulinaemic glucose clamp was used to assess insulin sensitivity.
